SPY389.46-2.40 -0.61%
DIA313.18-2.37 -0.75%
IXIC11,388.50-29.66 -0.26%

BRIEF-European Commission Approves Merck's Keytruda (Pembrolizumab)

reuters.com · 04/29/2022 07:00
BRIEF-European Commission Approves Merck's Keytruda (Pembrolizumab)

- Merck & Co Inc MRK:

  • EUROPEAN COMMISSION APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DEFICIENT MISMATCH REPAIR (DMMR) TUMORS IN FIVE DIFFERENT TYPES OF CANCER

  • MERCK - APPROVAL ALLOWS MARKETING OF KEYTRUDA MONOTHERAPY IN ALL EUROPEAN UNION MEMBER STATES PLUS ICELAND, LICHTENSTEIN, NORWAY AND NORTHERN IRELAND

Source text for Eikon: ID:nBw7cWW2wa

Further company coverage: MRK


((reuters.briefs@thomsonreuters.com;))